I’m not aware of any study that investigated the effects of Nattokinase on CAC. It’s benefits appear to be more upstream and more downstream of CAC evolution, but may not reverse CAC itself. Upstream: Nk has shown in clinical trials to put the brakes on lesion progression. These effects were investigated in carotid arteries where Ultrasound is the way to image atherosclerotic narrowing. Downstream: Nk has shown a strong fibrinolytic and antithrombotic effect. Which means that in case of plaque rupture, it may mitigate the thrombotic sequelae thereby preventing total occlusion and its consequences.

Given Nk’s favourable safety profile, supplementing with it is not a bad idea for individuals at elevated atherosclerotic risk.

K2: The answer to your question is not yet clear. Several trials are underway to establish K2’s effects on the progression of calcification, as K2 plays an important role in calcium homeostasis. One group of investigators, presenting their results during a conference last year, came to the conclusion that K2 has no effect in individuals with a low calcium score (<400 AU), but significantly delayed progression in those with a higher score. K2 had a significant effect on disease events, decreasing them in both groups.